Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Xencor Inc
Xencor Inc_20100107

Xencor Inc patents


Recent patent applications related to Xencor Inc. Xencor Inc is listed as an Agent/Assignee. Note: Xencor Inc may have other listings under different names/spellings. We're not affiliated with Xencor Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "X" | Xencor Inc-related inventors


Bispecific antibodies that bind to cd38 and cd3

The invention provides novel heterodimeric proteins including heterodimeric antibodies.... Xencor Inc

Treatment for chronic lymphocytic leukemia (cll)

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens.... Xencor Inc

Heterodimeric proteins

The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as... Xencor Inc

Optimized antibodies that target cd19

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.... Xencor Inc

Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases

The present disclosure relates to immunoglobulins that bind FcγRIIb+ B cells and coengage CD19 on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease.... Xencor Inc

Bispecific antibodies that bind cd20 and cd3

The present invention is directed to methods of administrating bispecific anti-CD20×anti-CD3 antibodies.... Xencor Inc

Bispecific antibodies that bind cd123 and cd3

The present invention is directed to novel bispecific anti-CD123 x anti-CD3 antibodies.... Xencor Inc

Novel compositions and methods for treating ige-mediated disorders

The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.... Xencor Inc

Heterodimeric antibodies that bind cd3 and psma

The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.... Xencor Inc

Complement component c5 antibodies

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure... Xencor Inc

Antibodies with modified isoelectric points

The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.... Xencor Inc

Novel immunoglobulin variants

The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.... Xencor Inc

Treatment for chronic lymphocytic leukemia (cll)

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level... Xencor Inc

Heterodimeric antibodies to cd3 x cd123

The present invention is directed to novel heterodimeric antibodies.... Xencor Inc

Heterodimeric antibodies to cd3 x cd123

The present invention is directed to novel heterodimeric antibodies.... Xencor Inc

Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens

Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.... Xencor Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Xencor Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Xencor Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###